During the last session, Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s traded shares were 3.38 million, with the beta value of the company hitting 2.03. At the end of the trading day, the stock’s price was $2.06, reflecting an intraday gain of 12.57% or $0.23. The 52-week high for the AUTL share is $6.62, that puts it down -221.36 from that peak though still a striking 18.45% gain since the share price plummeted to a 52-week low of $1.68. The company’s market capitalization is $548.21M, and the average trade volume was 1.40 million shares over the past three months.
Autolus Therapeutics plc ADR (AUTL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AUTL has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.24.
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
Autolus Therapeutics plc ADR (AUTL) registered a 12.57% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 12.57% in intraday trading to $2.06, hitting a weekly high. The stock’s 5-day price performance is 13.19%, and it has moved by -2.37% in 30 days. Based on these gigs, the overall price performance for the year is -66.93%.
The consensus price target of analysts on Wall Street is $7.6, which implies an increase of 72.89% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7.6 and $7.6 respectively. As a result, AUTL is trading at a discount of -268.93% off the target high and -268.93% off the low.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
In the rating firms’ projections, revenue will increase 920.38% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.98M as predicted by 6 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 500k by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 3.32%. While earnings are projected to return 24.89% in 2025, the next five years will return 17.01% per annum.
AUTL Dividends
Autolus Therapeutics plc ADR is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 20.49 million shares, is of BLACKSTONE INC.’s that is approximately 7.7006% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $71.29 million.
Also, the Mutual Funds coming in first place with the largest holdings of Autolus Therapeutics plc ADR (AUTL) shares are Vanguard Specialized-Health Care Fund and Fidelity Small Cap Growth Fund . Data provided on Oct 31, 2024 indicates that Vanguard Specialized-Health Care Fund owns about 19.36 shares. This amounts to just over 7.27 percent of the company’s overall shares, with a $39.87 million market value. The same data shows that the other fund manager holds slightly less at 2.57, or about 0.97% of the stock, which is worth about $5.3 million.
